<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Subcutaneous interferon beta-1a is a recognized treatment of relapsing multiple <z:mp ids='MP_0000612'>sclerosis</z:mp>, and it may delay the <z:hpo ids='HP_0003674'>onset</z:hpo> of definite multiple <z:mp ids='MP_0000612'>sclerosis</z:mp> in patients with a first clinical demyelinating episode </plain></SENT>
<SENT sid="1" pm="."><plain>Interferon beta-1a exerts beneficial effects on cognitive functioning via both short-term and long-term mechanisms </plain></SENT>
<SENT sid="2" pm="."><plain>The beneficial effect is thought to be a result of immune modulation, with inhibition of leukocyte proliferation and antigen presentation and an increased amount of interleukins </plain></SENT>
<SENT sid="3" pm="."><plain>The systemic side effects of interferon beta-1a are <z:e sem="disease" ids="C1558931" disease_type="Disease or Syndrome" abbrv="">flu-like syndrome</z:e> and development of neutralizing antibodies, the clinical significance of which is not known </plain></SENT>
<SENT sid="4" pm="."><plain>There have been concerns about the rare development of an <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0011303" disease_type="Disease or Syndrome" abbrv="">demyelinating disease</z:e> after interferon beta-1a therapy as a result of upregulation of <z:mp ids='MP_0002501'>inflammatory mediators</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>In the clinical trials, there is evidence of development of mild <z:hpo ids='HP_0001903'>anemia</z:hpo> with a <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> level below 10 g/dL only in 3% of the patients </plain></SENT>
<SENT sid="6" pm="."><plain>There has been no reported case of development of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> in patients being treated with interferon beta-1a </plain></SENT>
<SENT sid="7" pm="."><plain>Described here is a case of development of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> with interferon beta-1a in a patient with multiple <z:mp ids='MP_0000612'>sclerosis</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>Our patient underwent a complete hematologic evaluation to rule out other causes of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Association with interferon beta-1a was highly suspected </plain></SENT>
</text></document>